This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
Subscribe To Our Newsletter & Stay Updated
